Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy
Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared wit...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2017/5604891 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850166563314860032 |
|---|---|
| author | Julien Fleurence Sophie Fougeray Meriem Bahri Denis Cochonneau Béatrice Clémenceau François Paris Andras Heczey Stéphane Birklé |
| author_facet | Julien Fleurence Sophie Fougeray Meriem Bahri Denis Cochonneau Béatrice Clémenceau François Paris Andras Heczey Stéphane Birklé |
| author_sort | Julien Fleurence |
| collection | DOAJ |
| description | Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antigen for cancer immunotherapy with the regulatory approval of dinutuximab, a chimeric anti-GD2 therapeutic antibody. Although the therapeutic efficacy of anti-GD2 monoclonal antibodies is well documented, neuropathic pain may limit its application. O-Acetyl-GD2, the O-acetylated-derivative of GD2, has recently received attention as novel antigen to target GD2-positive cancers. The present paper examines the role of O-acetyl-GD2 in tumor biology as well as the available preclinical data of anti-O-acetyl-GD2 monoclonal antibodies. A discussion on the relevance of O-acetyl-GD2 in chimeric antigen receptor T cell therapy development is also included. |
| format | Article |
| id | doaj-art-e397588521e445a98b10cf7afd44ba5c |
| institution | OA Journals |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-e397588521e445a98b10cf7afd44ba5c2025-08-20T02:21:24ZengWileyJournal of Immunology Research2314-88612314-71562017-01-01201710.1155/2017/56048915604891Targeting O-Acetyl-GD2 Ganglioside for Cancer ImmunotherapyJulien Fleurence0Sophie Fougeray1Meriem Bahri2Denis Cochonneau3Béatrice Clémenceau4François Paris5Andras Heczey6Stéphane Birklé7Inserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, FranceInserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, FranceInserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, FranceInserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, FranceInserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, FranceInserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, FranceTexas Children’s Cancer Center, Baylor College of Medicine, Houston, TX, USAInserm U892, Centre de Recherche en Cancérologie de Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, Nantes, FranceTarget selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on their higher abundance in tumors when compared with the matched normal tissues. GD2 is the first ganglioside proven to be an effective target antigen for cancer immunotherapy with the regulatory approval of dinutuximab, a chimeric anti-GD2 therapeutic antibody. Although the therapeutic efficacy of anti-GD2 monoclonal antibodies is well documented, neuropathic pain may limit its application. O-Acetyl-GD2, the O-acetylated-derivative of GD2, has recently received attention as novel antigen to target GD2-positive cancers. The present paper examines the role of O-acetyl-GD2 in tumor biology as well as the available preclinical data of anti-O-acetyl-GD2 monoclonal antibodies. A discussion on the relevance of O-acetyl-GD2 in chimeric antigen receptor T cell therapy development is also included.http://dx.doi.org/10.1155/2017/5604891 |
| spellingShingle | Julien Fleurence Sophie Fougeray Meriem Bahri Denis Cochonneau Béatrice Clémenceau François Paris Andras Heczey Stéphane Birklé Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy Journal of Immunology Research |
| title | Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy |
| title_full | Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy |
| title_fullStr | Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy |
| title_full_unstemmed | Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy |
| title_short | Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy |
| title_sort | targeting o acetyl gd2 ganglioside for cancer immunotherapy |
| url | http://dx.doi.org/10.1155/2017/5604891 |
| work_keys_str_mv | AT julienfleurence targetingoacetylgd2gangliosideforcancerimmunotherapy AT sophiefougeray targetingoacetylgd2gangliosideforcancerimmunotherapy AT meriembahri targetingoacetylgd2gangliosideforcancerimmunotherapy AT deniscochonneau targetingoacetylgd2gangliosideforcancerimmunotherapy AT beatriceclemenceau targetingoacetylgd2gangliosideforcancerimmunotherapy AT francoisparis targetingoacetylgd2gangliosideforcancerimmunotherapy AT andrasheczey targetingoacetylgd2gangliosideforcancerimmunotherapy AT stephanebirkle targetingoacetylgd2gangliosideforcancerimmunotherapy |